Who We Are
Our two business units elevate standards of care with best-in-class devices for vision, women’s health, and surgical procedures.
Global Operations
We are a global company with more than 15,000 employees located in 130 countries across Europe, Asia, Africa, and the Americas. Our corporate headquarters are in San Ramon, CA.
Leadership
Our leadership team provides the expertise, passion and dedication that inspires success.
Executive Management Team
Albert G. White III
Brian Andrews
Daniel G. McBride, Esq.
Holly Sheffield
Jerry Warner
Albert G. White III
Brian Andrews
Daniel G. McBride, Esq.
Holly Sheffield
Jerry Warner
Colleen E. Jay
Albert G. White III
Robert S. Weiss
Teresa S. Madden
Maria Rivas, MD
Cynthia (Cindy) L. Lucchese
Lawrence E. Kurzius
Barbara Carbone
Walter Rosebrough Jr.
Walter Rosebrough Jr.
Director
Mr. Rosebrough currently serves as CEO Emeritus and Senior Advisor of STERIS plc (NYSE: STE), a global medical device business focused on infection prevention products and services. During his tenure as CEO of STERIS from 2007 to 2021, STERIS’s stock generated a 10-fold total return or an 18% annualized return compared with a 10% annualized return for the S&P 500, and the company’s market capitalization increased by over $20 billion. His career also includes nearly two decades at Hill-Rom Holdings, Inc., where he held senior executive positions, including President and CEO of Support Systems International and President and CEO of Hill-Rom. Mr. Rosebrough currently serves as Independent Chair on the Board of Varex Imaging (NASDAQ: VREX).
Mr. Rosebrough holds a Master of Business Administration from Stanford University, and a BIE from Kettering University.
Agostino Ricupati
Senior Vice President & Chief Accounting Officer
Mr. Ricupati has served as our Chief Accounting Officer since October 2017 and as Senior Vice President, Finance & Tax since July 2017. Mr. Ricupati previously served as Vice President, Tax for the Company from July 2013 to July 2017. Prior to joining Cooper, he served as International Tax Director for Intel Corp. (NASDAQ: INTC) from 2010 to 2013 and in various other senior finance and tax positions over the past 20 years. He holds a masters degree from DePaul University and is a Certified Public Accountant.
Albert G. White III
President & Chief Executive Officer
Mr. White has served as President & Chief Executive Officer and a member on our Board of Directors since May 2018. Previously, he served as Chief Financial Officer from November 2016 until his appointment as CEO and he also served as Executive Vice President and Chief Strategy Officer, positions he held from December 2015 and July 2011, respectively. From August 2015 to May 2018, Mr. White also directed our women’s healthcare business and served as Chief Executive Officer of Cooper Medical Inc., the parent company to CooperSurgical. Previously, he served as Vice President, Investor Relations from November 2007 through March 2013 and as Vice President and Treasurer from April 2006 through December 2012. Prior to joining the Company, Mr. White was a Director with KeyBanc Capital Markets for three years and held a number of leadership positions within KeyBank National Association over the prior eight years.
Mr. White also currently serves as a board member of Evolus Inc (NASDAQ: EOLS), a performance beauty company with a focus on building a portfolio of consumer brands, and is a member of its Compensation Committee, having been appointed in July 2024.
Mr. White holds a BS in Finance and an MBA, both from Virginia Tech.
Brian Andrews
Executive Vice President, Chief Financial Officer & Treasurer
Mr. Andrews has served as Executive Vice President, Chief Financial Officer & Treasurer since December 2020. He previously served as our Senior Vice President, Chief Financial Officer & Treasurer from May 2018, and as Treasurer since January 2013 and Vice President since November 2014. He also served as Vice President, Global Logistics and Service for CooperSurgical, a position he held from June 2017 to May 2018. Mr. Andrews previously served as Assistant Treasurer for the Company from April 2006 to December 2012. Prior to joining Cooper, he held various corporate and investment banking positions at KeyBanc Capital Markets from 2002 to 2006 and at ING Barings from 2000 to 2001. He holds a B.A. in Economics from Columbia University.
Colleen E. Jay
Chair of the Board
Ms. Jay served as a Global Division President for Procter and Gamble until her retirement in October 2017. Her most recent operational assignment was President, Global Beauty Specialty Business at Procter & Gamble from 2015 where she was responsible for the Wella Professional Salon, Cosmetics, Retail Hair Color, and Fragrance businesses, and the successful divestiture of them.
Prior to that, Ms. Jay led the multi-billion dollar Global Retail Hair Care and Color division of Procter & Gamble from 2012 to 2015 and the Global Female Beauty division from 2010 to 2012.
She also served as Vice President & General Manager, Greater China Feminine Care, Personal Cleansing, Oral Care & Entire China Marketing Function, based in Guangzhou, China, from
2006 to 2009, where she was responsible for businesses with a combined value of over $1 Billion.
She worked in various positions with Procter & Gamble since July 1985 and has led operational units in the United States, Canada, China, and Switzerland (including leading global businesses) during the course of her career. Ms. Jay has also volunteered at Catalyst, Inc., a non-profit organization dedicated to improving workplace inclusion for women.
Ms. Jay serves on the board of Treasury Wine Estates (ASX:TWE), a publicly traded company making and selling wine for the global market. She also serves on the board of Beyond Meat,
Inc. (NASDAQ: BYND) and is a member of its audit committee.
Ms. Jay graduated with honors from Wilfrid Laurier University with a bachelor’s degree in business administration.
Daniel G. McBride. Esq.
Chief Operating Officer & General Counsel
Mr. McBride has served as Executive Vice President and Chief Operating Officer since November 2013, as General Counsel since September 2025 and Corporate Secretary since October 2025. He previously served as President of CooperVision, our contact lens subsidiary from February 2014 through February 2022, as our Chief Risk Officer from July 2011 through October 2013, as our General Counsel from November 2007 through January 2014, and as Vice President from July 2006 through October 2013. He also served as Senior Counsel from February 2005 through November 2007. Prior to joining Cooper, Mr. McBride was an attorney with Latham & Watkins LLP from October 1998 to February 2005, concentrating on mergers and acquisitions and corporate finance matters. He holds a B.S. in Finance from Santa Clara University and a J.D. from Stanford Law School.
Gary S. Petersmeyer
Director
Mr. Petersmeyer currently serves as a consultant to companies in the pharmaceutical and medical device industries. Most recently he co-founded Aesthetic Sciences Corporation in 2004 and served as the Chief Executive Officer and Chairman until December 2010. Prior to that he served as President and Chief Operating Officer of Pherin Pharmaceuticals, Inc. from 2000 to 2001 and as President and Chief Operating Officer of Collagen Corporation, Inc. from 1995 to 1997 and as Chief Executive Officer from 1997 to 1999. From 1976 to 2000 he served in various management positions for pharmaceutical and medical device companies.
Mr. Petersmeyer served as a director and member of the compensation and audit committees of Omnicell, Inc. (NASDAQ: OMCL) from January 2007 through February 2019. He also served as director and chairman of the board of Cardica, Inc. (NASDAQ: CRDC) through November 2015. He has previously served on the boards of Visx Incorporated and Roxro Pharmaceuticals prior to their acquisitions. He also served as chairman of the board for Positive Coaching Alliance, a non-profit organization dedicated to improving youth sports.
Holly Sheffield
President of CooperSurgical
Ms. Sheffield has served as President of CooperSurgical, Inc., our women's healthcare business, since July 2020. Previously, she served as Executive Vice President & Chief Strategy Officer from June 2018 to July 2020. Prior to joining Cooper, Ms. Sheffield had over 20 years of experience in investment banking. She joined Cooper from UBS Securities LLC, where she was a Managing Director, Global Head of Medical Technology from 2009 to May 2018. From 2000 to 2009, Ms. Sheffield was at Credit Suisse and from 1997-2000, Ms. Sheffield was at Donaldson, Lufkin & Jenrette until it was acquired by Credit Suisse. Ms. Sheffield received a B.S. from Cornell University and an M.B.A. from Columbia Business School.
Jerry Warner
President of CooperVision
Mr. Warner has served as President, CooperVision, Inc. from February 2022. He previously served as Executive Vice President, Americas & Global Commercial Functions of CooperVision from April 2019 to January 2022 and as President, Americas from May 2015 to March 2019. Mr. Warner served in various other Vice President and Senior Vice President positions with CooperVision from May 2012 through April 2015. Prior to joining CooperVision, Mr. Warner spent 17 years at Bausch + Lomb in a variety of marketing and management roles. Mr. Warner earned a Bachelor of Science – Business Administration in Marketing from Villanova University and an MBA from The Simon School of Business – University of Rochester.
Maria Rivas, MD
Director
Dr. Rivas served as Global Chief Medical Affairs Officer for Specialty and Primary Care and Head, Evidence Generation for Pfizer, Inc. (NYSE: PFE) from September 2022 until March 2025. Prior to her role at Pfizer, she served as Chief Medical Officer and Senior Vice President for the healthcare business of Merck KGaA, Darmstadt, Germany (which operates as EMD Serono in the US and Canada) from January 2019 to September 2022 where she led the Global Pharmacovigilance, Medical Affairs and Evidence and Value Development (HEOR) teams in over 90 countries. Prior to that, Dr. Rivas served as Senior Vice President of Global Medical Affairs at Merck & Co (MSD), as Vice President of Global Medical Affairs at Abbvie, as Vice President of Oncology, General Medicine and Diagnostic Imaging Medical Affairs at Bayer Healthcare, and in various roles at Eli Lilly including Head of US Women’s Health Medical Affairs. Before joining Eli Lilly, Dr. Rivas was in private practice as an endocrinologist in Puerto Rico.
Dr. Rivas served as a director for Medidata (NASDAQ: MDSO), a public, mid-cap health technology company, until its successful merger with Dassault Systèmes, and served as a member of the audit and compensation committees.
Dr. Rivas obtained a BA in Biochemistry from Brandeis University, Waltham, MA and an MD from Columbia University’s Vagelos College of Physicians and Surgeons, New York, NY. She completed a residency in Internal Medicine and a fellowship in Endocrinology at NY- Presbyterian Hospital, New York, NY. Dr. Rivas is board certified in Endocrinology, Diabetes and Metabolism.
Robert S. Weiss
Director
Mr. Weiss served as our President from March 2008 and as our Chief Executive Officer from
November 2007 until his retirement in May 2018. He also served as President of CooperVision,
our contact lens subsidiary, from March 2007 to February 2008. He previously served as our
Chief Operating Officer from January 2005 to October 2007 and as Executive Vice President
from October 1995 to October 2007. He served as our Chief Financial Officer from September
1989 to January 2005. He served as our Treasurer from 1989 to March 2002.
Mr. Weiss served as a director of Accuray Incorporated (Nasdaq: ARAY), a company that
develops, manufactures, and sells precise, innovative tumor treatment solutions with the aim of helping patients live longer, better lives, until November 2019. He served on its nominating and
governance committee and on its audit committee. He also served as a member of the Board of
Trustees of the University of Scranton in Pennsylvania until May 2021, including service on its finance, advancement, and audit committees.
Mr. Weiss holds a BS in accounting from the University of Scranton.
Teresa S. Madden
Director
Ms. Madden served as Executive Vice President and Chief Financial Officer of Xcel Energy, Inc. (NASDAQ:XEL), an electric and natural gas utility, from 2011 until her retirement in 2016. She joined Xcel in 2003 as Vice President, Finance, Customer & Field Operations and was named Vice President and Controller in 2004. Previously, she served as Controller for Rogue Wave Software, Inc. from 2000 to 2003 and as Controller for New Century Energies and Public Service Company of Colorado, predecessor companies of Xcel Energy. Ms. Madden holds a Bachelor of Science in Accounting from Colorado State University and a Master of Business Administration from Regis University.
Ms. Madden serves on the board of Enbridge, Inc. (NYSE: ENB) and serves on the governance committee and as chair of the audit, finance and risk committee. She previously served as a director for Peabody Energy Corporation (NYSE:BTU) from 2017 to 2020 where she served on the health, safety, security & environmental committee and as chair of the audit committee.
William (Bill) A. Kozy
Vice Chairman and Lead Director
Mr. Kozy served as the Chief Operating Officer of Becton Dickinson (NYSE: BDX) from 2012 until his retirement in 2016, and as its Executive Vice President from 2006 until 2016. He also served as a member of the corporate Leadership Team for Becton Dickinson and in various executive roles since 1988, including Senior Vice President of Company Operations from 1998 until 2002, President of BD Diagnostics from 2002 through 2006, President of the BD Biosciences segment from 2006 to 2009 and head of BD Medical from 2009 through 2011.
Mr. Kozy is the chairman of the board of directors of LivaNova PLC (NASDAQ:LIVN), a publicly traded medical device company focused on neurological and cardiovascular medicine. He also serves on the nominating and corporate governance committee. He also serves as a senior advisor to McKinsey & Company, a global management firm, with a focus on mergers and acquisitions.
Nicholas S. Khadder
General Counsel & Corporate Secretary
Mr. Khadder has served as General Counsel & Corporate Secretary since August 2022. He previously served as general counsel of Standard BioTools Inc. (formerly Fluidigm Corporation) from June 2016 to July 2022. From 2010 to June 2016, he held various positions at Amyris, Inc., including general counsel and corporate secretary from 2013 to June 2016. Previously, he served in senior corporate counsel roles at LeapFrog Enterprises, Inc. from August 2008 to September 2010, and at Protiviti Inc. (a subsidiary of Robert Half International Inc.) from June 2005 to July 2008. Mr. Khadder started his legal career as a corporate attorney at Fenwick & West LLP from October 1998 to May 2005. He holds a Juris Doctor degree from the University of California, Berkeley, School of Law and an A.B. in English from the University of California, Berkeley.
Cynthia (Cindy) L. Lucchese
Director
Ms. Lucchese served as Chief Strategy Officer for Penske Entertainment Corp (previously Hulman and Company), a subsidiary of Penske Corporation, from November 2020 until her retirement in February 2023, and she served as Chief Administrative Officer and Chief Financial Officer from November 2014 to November 2020. Previously, she was Senior Vice President and Chief Financial Officer of Hillenbrand (NYSE: HI) from 2008 to 2014. She also served from 2005 to 2007 as Senior Vice President and Chief Financial Officer of Thoratec (NASDAQ: THOR), a medical device company focused on treating advanced stage heart failure, and she held various senior financial positions with Guidant Corporation (NYSE: GDT), now a part of Boston Scientific, from 1994 to 2005.
Ms. Luchesse is a member of the board of BVI Medical, a private global ophthalmic device company and serves as chair of the audit committee. She is a member of the board of Microtransponder, a private medical device company focused on chronic stroke recovery and serves as chair of the audit committee.
Ms. Lucchese previously served on the board of Inari Medical (NASDAQ: NARI), a company focused on the treatment of venous thromboembolism and other venous diseases, from November, 2019 until its acquisition by Stryker in February 2025, where she chaired the nominating & corporate governance committee and the audit committee. She also served on the board of Relievant Medsystems, Inc., a private medical device company focused on the treatment of spinal pain, from 2022 until its sale to Boston Scientific in November 2023, where she was chair of the audit committee. Ms. Luchesse also served on the board of Hanger, Inc. (NYSE: HNGR), a provider of orthotic and prosthetic care services and products, until its acquisition in October 2022 by Patient Square Capital, where she served on the audit and compensation committees, and on the board of Intersect ENT (NASDAQ: XENT) from 2014 until its acquisition by Medtronic, Inc. in 2022, where she served as chair of the audit committee and a member of the nominating & corporate governance committee. She also served on the board of Brightpoint, Inc. (NASDAQ: CELL) from 2009 until its acquisition by Ingram Micro, Inc. in 2012, where she served as chair of the audit committee and a member of the nominating & corporate governance committee. Ms. Luchesse served on the Board of Trustees for Indiana University from 2021 to 2025, as vice chair of the board and chair of the finance and audit committee.
Ms. Lucchese earned her undergraduate degree in accounting and MBA from the Indiana University Kelley School of Business.
Lawrence E. Kurzius
Director
Mr. Kurzius served as the Chief Executive Officer of McCormick & Company, Incorporated (NYSE: MKC) from 2016 to 2023 and as its President from 2015 to 2022. He previously held roles of increasing responsibility at McCormick beginning in 2003, including President and Chief Operating Officer (2015-2016), President of McCormick’s global consumer business (2013-2016), Chief Administrative Officer (2013-2015), President of the international business (2008-2013), and President of EMEA (2007-2008). Previously, Mr. Kurzius was the Chief Executive Officer of Zatarain’s, where he worked for 12 years before the company was acquired by McCormick. Prior to this, Mr. Kurzius was a marketing executive with the Quaker Oats Company and Mars Inc.’s Uncle Ben’s Company.
Mr. Kurzius currently serves as the Chairman of the Board of Elanco Animal Health Inc. (NYSE: ELAN) since 2024, and served as a member of its board as well as on its corporate governance committee and as chair of its compensation and human capital committee since 2018. He also serves on the board of Lamb Weston (NYSE: LW), as well as on its compensation and human capital committee and nominating and corporate governance committee, since July 2025. Mr. Kurzius previously served as a member of the board of McCormick until 2025, as the Executive Chairman from 2023 to 2024 and as the Chairman from 2017 to 2023.
Mr. Kurzius graduated from Princeton University magna cum laude with a degree in economics.
Barbara Carbone
Director
Ms. Carbone served as an Audit Partner at KMPG LLP until her retirement in 2019. She served on the KPMG Partnership Audit Committee for six years, including three years as the chairperson, and as the Partner in Charge of Human Resources for the Audit Practice, involved in designing performance management processes, compensation strategies, and training and development programs.
Ms. Carbone currently serves as board chair and audit committee chair at TrueCar, Inc. (NASDAQ: TRUE), and as a member of the board of directors, chair of the audit & finance committee, and member of the compensation committee of Limoneira Company (NASDAQ: LMNR). She also serves on the board of directors and is chair of the audit committee of Bob’s Discount Furniture.
Previously, Ms. Carbone served on the board of directors and member of the audit committee and chair of the compensation committee of DZS Inc. (NASDAQ: DZSI) from January 2021 through March 2025. From September 1998 through December2019, she served as a member of the board of directors and chair of the audit committee of the Women’s Business Enterprise National Council. She also served on the board of trustees of the Exploratorium, a museum of science, technology, and arts in San Francisco, from 2008 through 2023.
Ms. Carbone holds a B.S. in Business Administration (Accountancy) from California State University at Sacramento.
